News
Displaying 251–260 of 537
-
A Eureka Moment for Paul Yang Boosts Advancement of Vision-Saving RP Drug
Research NewsHis latest Foundation grant is helping move the drug toward a clinical trial
-
Are You on the Clinical Trial Radar Screen?
Research NewsTherapy developers use the My Retina Tracker Registry to recruit for human studies of emerging therapies
-
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
In the PressFormer Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
-
Very-Long-Chain Polyunsaturated Fatty Acids Improve Vision in Mice with a Form of Stargardt Disease
Research NewsResearchers believe the VLC-PUFAs may benefit people with autosomal dominant Stargardt disease, AMD, and possibly other retinal degenerations
-
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
In the PressDevelopment of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
-
Research News
The company plans to enroll additional patients as young as four years old
-
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Research NewsCompany will seek marketing approval for the emerging therapy
-
Foundation News
In honor of Rare Disease Day, this February 28th virtual event will raise awareness and fund research leading to treatments and cures for blinding retinal diseases.
-
ProQR Completes Enrollment in Phase 2/3 Clinical Trial of RNA Therapy for LCA10
Research NewsCompany also announced progress in enrollment for Phase 1 / 2 clinical trials for emerging USH2A and RHO RNA therapies.
-
REGENXBIO’s Wet AMD Gene Therapy Moving into Phase 3 Trials
Research NewsIn a Phase ½ clinical trial, the emerging treatment reduced the burden of regular anti-VEGF injections
